Cilostazol and Endothelial Progenitor Cell

Gyeongsang National University Hospital60 enrolled

Overview

To assess impact of adjunctive cilostazol on endothelial progenitor cell (EPC) mobilization in patients with acute myocardial infarction (To reveal the role of cilostazol in up-regulation of EPC count)

Primary endpoint: % Change of EPC count Secondary endpoints: 1. Changes of ADP/AA/collagen-induced PFT 2. Changes of lipid profile and high sensitivity-C-reactive protein 3. Change of TEG measurements 4. Change of PWV 5. Predictors of EPC count (baseline and 1-month) 6. ischemic (CV death, MI \& stroke) and bleeding events (BARC)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Myocardial Infarction, Acute

Interventions

Cilostazol TabletsDRUG

Cilostazol-SR, capsule, 200mg, once daily, 30 days.

placeboDRUG

Placebo, tablet, 200mg, once daily, 30 days.

AspirinDRUG

Astrix, capsule,100mg, once daily, 30 days.

Clopidogrel

Eligibility

Sex: ALLMin age: 20 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * naïve AMI * undergoing successful coronary stent implantation Exclusion Criteria: * high-risk patients for thrombotic event; * a history of active bleeding or bleeding diatheses; * contraindication to antiplatelet therapy; * hemodynamic or electrical instability; * oral anticoagulation therapy; * left ventricular ejection fraction \< 30%; * leukocyte count \< 3,000/mm3 and/or platelet count \< 100,000/mm3; * AST or ALT \> 3 times the respective the upper limit; * serum creatinine level \> 3.5 mg/dL; * stroke within 3 months; * pregnancy; * non-cardiac disease with a life expectancy \< 1 year; * any patients not tolerable or suitable for coronary intervention; and * inability to follow the protocol